KRRO a biotech company with earnings coming LONG

Zaktualizowano
KRRO is in the biotechnology space in the gene-editing realm. It is in portfolios of C. Woods .

A recent analyst gave it an upside to 100 which is very favorable given its product line and track

record with an all-time high of about $250 ( which is about 450% over current valuation)

On the one-hour time frame, it has had a great week and is breaking out over its moving

averages as well as bullish momentum on the dual TF RSI indicator. This is a stock-long trade

in the biotechnology sector which is prognosticated to be among the best of 2024. The dramatic

reversal on the chart tells me this is a long entry. Targeting $57.5 in the short term and

$75.00 for most of the position in consideration of the analyst report.
Zlecenie aktywne
Price is currently 15-17% below a significant level of resistance which could potentially be broken.
Zlecenie aktywne
If KRRO can break through 54 then I see room to 59 at the top of the high volume area of the volume profile.

snapshot
biotechnologyBreadth IndicatorsCentered OscillatorsDNAFibonaccigeneeditinggenetherapykrrpLABUreversalRNAXBI

Wyłączenie odpowiedzialności